Hypertrophic cardiomyopathy anatomic abnormalities: Difference between revisions
No edit summary |
No edit summary |
||
| Line 1: | Line 1: | ||
{{Hypertrophic cardiomyopathy}} | {{Hypertrophic cardiomyopathy}} | ||
'''Editors-In-Chief:''' [[C. Michael Gibson, M.S., M.D.]] [mailto:mgibson@perfuse.org] | '''Editors-In-Chief:''' [[C. Michael Gibson, M.S., M.D.]] [mailto:mgibson@perfuse.org] | ||
==Overview== | ==Overview== | ||
Revision as of 23:36, 12 August 2011
|
Hypertrophic Cardiomyopathy Microchapters |
|
Differentiating Hypertrophic Cardiomyopathy from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Hypertrophic cardiomyopathy anatomic abnormalities On the Web |
|
Hypertrophic cardiomyopathy anatomic abnormalities in the news |
|
Directions to Hospitals Treating Hypertrophic cardiomyopathy |
|
Risk calculators and risk factors for Hypertrophic cardiomyopathy anatomic abnormalities |
Editors-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Individuals with HCM have some degree of left ventricular hypertrophy. In approximately 2/3rds of cases this is an asymmetric hypertrophy, involving the inter-ventricular septum, and is known as asymmetric septal hypertrophy (ASH). This is in contrast to the concentric hypertrophy seen in aortic stenosis or hypertension.
The degree of ventricular involvement is variable ranging from diffuse involvement of both ventricles to isolated involvement of a portion of one segment of the LV.
Data from two large registries indicates that;
- 55% of cases involve the septum and anterolateral free wall,
- 20% involve the entire septum alone,
- 10% are limited to the basal septum and 15% are limited to the apical or distal LV (Yamaguchi variant).
Some genetic variants may manifest very little overt LVH but have an increased risk of sudden cardiac death (SCD).